[ad_1]
Celltrion anti-treatment targets supply early next year
◆ …[사진=연합뉴스]
The government predicted that the AstraZeneca vaccine will be the fastest among the new vaccines against coronavirus infection (Corona 19).
In a regular briefing on the 14th, Jung Eun-kyung, director of the Centers for Disease Control and Prevention, said: “We are working hard to start vaccinating COVID-19 before March next year,” Astra said. . He said: “The AstraZeneca vaccine is produced in Korea and is expected to be the fastest in terms of delivery time.”
“Of course, we continue to negotiate the timing of the supply of other vaccines,” he added.
He said: “With regard to vaccine approval, the European Union (EU) clinical approval process and the World Health Organization (WHO) verification process are reviewed and administered by the Ministry of Safety. Food and Drug Administration, and the situation is preparing for immediate vaccination. ” Explained.
Regarding the development of home treatments, he said, “The antibody treatment development program will be the fastest.”
He said: “In the case of antibody therapy, if given early on, it is expected to have the effect of preventing ‘severe progression’ that progresses to severe and leads to death.”
Celltrion, which completed phase 2 clinical trials on the anti-treatment ‘CT-P59’ on November 25, is reportedly targeting domestic supply in early 2021 after requesting conditional approval within this year.
The government has already completed a contract with AstraZeneca, and Pfizer, Johnson & Johnson-Jansen and Modena have already confirmed the amount of the purchase.
In this regard, he explained, “at least two or more are currently in talks on the review of the contract with the aim of completing the contract before the end of the year.”
Regarding the government’s quest to secure additional volume in addition to the 44 million currently insured vaccines, he said: “We continue to discuss additional quantities with pharmaceutical companies.” “The additional volume has yet to be confirmed.” said.
